MedTrace Logo

Assessment of Efficacy of AZD2281 in Platinum Sensitive Relapsed Serous Ovarian Cancer

NCT00753545 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 265

Last updated 2025-02-03

Study results available
· View outcomes & findings →

Summary

The primary purpose of this study to determine if AZD2281 is effective and well tolerated in maintaining the improvement in your cancer after previous platinum-based chemotherapy

Conditions

Interventions

DRUG

AZD2281

Tablets Oral BID

DRUG

matching placebo

matching placebo bid

Sponsors & Collaborators

Principal Investigators

  • Mika Sovak, BSc, MBCHB, MD · AstraZeneca

  • Prof Jonathan A Lederman · University College, London

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
130 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-08-28
Primary Completion
2010-06-30
Completion
2023-10-12

Countries

  • United States
  • Australia
  • Austria
  • Belgium
  • Canada
  • Czechia
  • Estonia
  • France
  • Germany
  • Israel
  • Netherlands
  • Poland
  • Romania
  • Russia
  • Spain
  • Ukraine
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00753545 on ClinicalTrials.gov